190 related articles for article (PubMed ID: 28214089)
1. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
[TBL] [Abstract][Full Text] [Related]
2. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
[TBL] [Abstract][Full Text] [Related]
3. Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
Patel SH; Batchala PP; Muttikkal TJE; Ferrante SS; Patrie JT; Fadul CE; Schiff D; Lopes MB; Jain R
J Neurooncol; 2021 May; 152(3):523-531. PubMed ID: 33661425
[TBL] [Abstract][Full Text] [Related]
4. Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase-Mutant Glioblastoma: A Multicenter Study.
Uetani H; Azuma M; Khant ZA; Watanabe Y; Kudo K; Kadota Y; Yokogami K; Takeshima H; Kuroda JI; Shinojima N; Hamasaki T; Mukasa A; Hirai T
J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):659-665. PubMed ID: 36877775
[TBL] [Abstract][Full Text] [Related]
5. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
6. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
7. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
8. IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
Choi Y; Nam Y; Lee YS; Kim J; Ahn KJ; Jang J; Shin NY; Kim BS; Jeon SS
Eur J Radiol; 2020 Jul; 128():109031. PubMed ID: 32417712
[TBL] [Abstract][Full Text] [Related]
9. Methodological issues on reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Sabour S
J Clin Neurosci; 2018 Apr; 50():298-299. PubMed ID: 29396064
[No Abstract] [Full Text] [Related]
10. Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas.
Su CQ; Lu SS; Zhou MD; Shen H; Shi HB; Hong XN
Clin Radiol; 2019 Feb; 74(2):154-160. PubMed ID: 30391048
[TBL] [Abstract][Full Text] [Related]
11. A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.
Su X; Sun H; Chen N; Roberts N; Yang X; Wang W; Li J; Huang X; Gong Q; Yue Q
Clin Radiol; 2020 Dec; 75(12):963.e7-963.e15. PubMed ID: 32921406
[TBL] [Abstract][Full Text] [Related]
12. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
13. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
14. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
[TBL] [Abstract][Full Text] [Related]
15. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
16. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
[TBL] [Abstract][Full Text] [Related]
17. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
19. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
[TBL] [Abstract][Full Text] [Related]
20. Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
Li ZC; Bai H; Sun Q; Zhao Y; Lv Y; Zhou J; Liang C; Chen Y; Liang D; Zheng H
Cancer Med; 2018 Dec; 7(12):5999-6009. PubMed ID: 30426720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
